Carlos Zamudio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Carlos Zamudio has a total of 188 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Seas
Universidad Peruana Cayetano Heredia
16 shared publications Eduardo Gotuzzo
Universidad Peruana Cayetano Heredia, Lima, Peru
8 shared publications- Fiorella Krapp
Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia
5 shared publications - Larissa Otero
Facultad de Medicina, Universidad Peruana Cayetano Heredia , Lima
5 shared publications E. Gotuzzo
Instituto de Medicina Tropical Alexander von Humboldt,Universidad Peruana Cayetano Heredia,Lima,Perú
4 shared publications- Cesar Ugarte-Gil
Affiliations Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru, Department of Epidemiology, The University of Texas Medical Branch, Galveston, Texas, United States of America
3 shared publications
Latest Publications
- Open Access
- 9 January 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 22
Genomic epidemiology of SARS-CoV-2 in Peru from 2020 to 2024
Background: Peru recorded one of the world’s highest COVID-19 mortality rates, with nearly 4.5 million reported cases and 220,000 deaths by March 2024. Understanding the emergence and spread of SARS-CoV-2 variants in this context is key to informing effective public health responses. This study describes the genomic diversity, transmission dynamics, and geographic spread of SARS-CoV-2 in Peru from 2020 to 2024. Methods: We analyzed nearly 50,000 high-quality public SARS-CoV-2 genome sequences collected nationwide between March 2020 and March 2024. Phylogeographic and mutational analyses were performed to identify variant lineages, trace their origins, and map viral movements within and beyond Peru. Results: We show that Peru’s epidemic waves were shaped by the emergence of locally evolved variants, including Lambda (C.37), Gamma (P.1.12), and Omicron (XBB.2.6 and DJ.1) sub-lineages. The city of Lima acted as the primary hub for inter-regional spread, accounting for 47.3% of inferred viral movements to other departments, notably Ancash, Cusco, and Piura. Peru was the source of various lineages that spread internationally, primarily to Chile, the USA, and Europe. Mutational analysis highlighted critical mutations in the spike protein, including L452Q and F490S in Lambda, associated with immune evasion and increased transmissibility. Conclusions: This work demonstrates the capacity of genomic surveillance in Peru to detect and track emerging SARS-CoV-2 variants, providing insights into regional and global transmission dynamics in a high-transmission, middle-income country setting. Sustained, cost-effective genomic monitoring, combined with strengthened bioinformatics and laboratory capacity, is essential for pandemic preparedness in resource-limited settings.
- 9 January 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 22
Open AccessGenomic epidemiology of SARS-CoV-2 in Peru from 2020 to 2024
Background: Peru recorded one of the world’s highest COVID-19 mortality rates, with nearly 4.5 million reported cases and 220,000 deaths by March 2024. Understanding the emergence and spread of SARS-CoV-2 variants in this context is key to informing effective public health responses. This study describes the genomic diversity, transmission dynamics, and geographic spread of SARS-CoV-2 in Peru from 2020 to 2024. Methods: We analyzed nearly 50,000 high-quality public SARS-CoV-2 genome sequences collected nationwide between March 2020 and March 2024. Phylogeographic and mutational analyses were performed to identify variant lineages, trace their origins, and map viral movements within and beyond Peru. Results: We show that Peru’s epidemic waves were shaped by the emergence of locally evolved variants, including Lambda (C.37), Gamma (P.1.12), and Omicron (XBB.2.6 and DJ.1) sub-lineages. The city of Lima acted as the primary hub for inter-regional spread, accounting for 47.3% of inferred viral movements to other departments, notably Ancash, Cusco, and Piura. Peru was the source of various lineages that spread internationally, primarily to Chile, the USA, and Europe. Mutational analysis highlighted critical mutations in the spike protein, including L452Q and F490S in Lambda, associated with immune evasion and increased transmissibility. Conclusions: This work demonstrates the capacity of genomic surveillance in Peru to detect and track emerging SARS-CoV-2 variants, providing insights into regional and global transmission dynamics in a high-transmission, middle-income country setting. Sustained, cost-effective genomic monitoring, combined with strengthened bioinformatics and laboratory capacity, is essential for pandemic preparedness in resource-limited settings.
- Open Access
- 28 March 2025
- Published by Universidad Peruana Cayetano Heredia in Revista Médica Herediana
- Vol. 36 (1) , 95-97
Influenza y mortalidad en adultos mayores: Un llamado a la acción sanitaria
- 28 March 2025
- Published by Universidad Peruana Cayetano Heredia in Revista Médica Herediana
- Vol. 36 (1) , 95-97
Open AccessInfluenza y mortalidad en adultos mayores: Un llamado a la acción sanitaria
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
Spatial proteomics and cell‐type specific changes in the basal ganglia of different neuropathologic vascular dementing lesions
Background: Vascular dementia (VD) is the second most common cause of dementia behind Alzheimer’s disease. VD has been associated with various cardiovascular maladies, which are thought to contribute to the white matter abnormalities associated with dementia. Cerebrovascular impairment disrupts CNS blood supply resulting in inflammation, oxidative stress, and hypoxia. The aim of this project is to study the impact of the cytotoxic environment created by disruptions to the CNS vasculature, which could be detrimental to glial (microglia, astrocyte) viability and function. We examined age and sex‐matched VD and control human autopsy brain from the Honolulu Asia Aging Study.Method: Utilizing Nanostring’s GeoMx™ Digital Spatial Profiling (DSP), we analyzed autopsy brain to compare neuropathologic vascular dementia lesions (lacunar, macro, and chronic microinfarcts) in the basal ganglia across the disease spectrum (absent/mild, moderate, severe). DSP enables spatial analysis of expression levels for 73 proteins in multiple regions of interest on formalin‐fixed paraffin‐embedded sections. Morphology markers were IBA1 (microglia) and GFAP (astrocytes) (Figure 1a‐b).Indica Labs’ HALO object co‐localization module was used to determine astrocyte, microglia, and total nuclei counts.Result: For chronic microinfarct severity, astrocyte and microglial counts decreased as the number of microinfarcts increased. By contrast, for macroinfarcts, astrocyte counts increased in addition to microglia steadily decreasing as the number of macroinfarcts increased. Analyses comparing increasing chronic microinfarct severity revealed numerous proteins with differential expression in both microglia and astrocytes, including pTauS404, IDE, p62, ATG5 and P2RX7 (Figure 2 microglia; Figure 3 astrocytes).Conclusion: Using a spatial proteomic technique, we demonstrated that various vascular dementing lesions have unique glial autophagy and inflammatory profiles at different disease stages. Overall, lower levels of vascular dementia lesions display lower levels of inflammation and increased upregulation of protective pathways that may contribute to maintenance of cognitive function. We also demonstrated basal ganglia cell population changes across different disease severities for chronic microinfarcts and macroinfarcts. Findings suggest that there is progressive astrocyte and microglial loss in the setting of chronic microinfarcts and increased astrogliosis in the setting of macroinfarcts. Whether there is a definitive inverse relationship in astrocyte counts between chronic microinfarcts and macroinfarcts remains unclear.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
Open AccessSpatial proteomics and cell‐type specific changes in the basal ganglia of different neuropathologic vascular dementing lesions
Background: Vascular dementia (VD) is the second most common cause of dementia behind Alzheimer’s disease. VD has been associated with various cardiovascular maladies, which are thought to contribute to the white matter abnormalities associated with dementia. Cerebrovascular impairment disrupts CNS blood supply resulting in inflammation, oxidative stress, and hypoxia. The aim of this project is to study the impact of the cytotoxic environment created by disruptions to the CNS vasculature, which could be detrimental to glial (microglia, astrocyte) viability and function. We examined age and sex‐matched VD and control human autopsy brain from the Honolulu Asia Aging Study.Method: Utilizing Nanostring’s GeoMx™ Digital Spatial Profiling (DSP), we analyzed autopsy brain to compare neuropathologic vascular dementia lesions (lacunar, macro, and chronic microinfarcts) in the basal ganglia across the disease spectrum (absent/mild, moderate, severe). DSP enables spatial analysis of expression levels for 73 proteins in multiple regions of interest on formalin‐fixed paraffin‐embedded sections. Morphology markers were IBA1 (microglia) and GFAP (astrocytes) (Figure 1a‐b).Indica Labs’ HALO object co‐localization module was used to determine astrocyte, microglia, and total nuclei counts.Result: For chronic microinfarct severity, astrocyte and microglial counts decreased as the number of microinfarcts increased. By contrast, for macroinfarcts, astrocyte counts increased in addition to microglia steadily decreasing as the number of macroinfarcts increased. Analyses comparing increasing chronic microinfarct severity revealed numerous proteins with differential expression in both microglia and astrocytes, including pTauS404, IDE, p62, ATG5 and P2RX7 (Figure 2 microglia; Figure 3 astrocytes).Conclusion: Using a spatial proteomic technique, we demonstrated that various vascular dementing lesions have unique glial autophagy and inflammatory profiles at different disease stages. Overall, lower levels of vascular dementia lesions display lower levels of inflammation and increased upregulation of protective pathways that may contribute to maintenance of cognitive function. We also demonstrated basal ganglia cell population changes across different disease severities for chronic microinfarcts and macroinfarcts. Findings suggest that there is progressive astrocyte and microglial loss in the setting of chronic microinfarcts and increased astrogliosis in the setting of macroinfarcts. Whether there is a definitive inverse relationship in astrocyte counts between chronic microinfarcts and macroinfarcts remains unclear.
- Open Access
- 1 November 2020
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 100, 95-103
A pragmatic stepped-wedge cluster randomized trial to evaluate the effectiveness and cost-effectiveness of active case finding for household contacts within a routine tuberculosis program, San Juan de Lurigancho, Lima, Peru
- 1 November 2020
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 100, 95-103
Open AccessA pragmatic stepped-wedge cluster randomized trial to evaluate the effectiveness and cost-effectiveness of active case finding for household contacts within a routine tuberculosis program, San Juan de Lurigancho, Lima, Peru
- 6 February 2017
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 145 (6) , 1107-1117
Cost-effectiveness of active case-finding of household contacts of pulmonary tuberculosis patients in a low HIV, tuberculosis-endemic urban area of Lima, Peru
SUMMARY We compared the cost-effectiveness (CE) of an active case-finding (ACF) programme for household contacts of tuberculosis (TB) cases enrolled in first-line treatment to routine passive case-finding (PCF) within an established national TB programme in Peru. Decision analysis was used to model detection of TB in household contacts through: (1) self-report of symptomatic cases for evaluation (PCF), (2) a provider-initiated ACF programme, (3) addition of an Xpert MTB/RIF diagnostic test for a single sputum sample from household contacts, and (4) all strategies combined. CE was calculated as the incremental cost-effectiveness ratio (ICER) in terms of US dollars per disability-adjusted life years (DALYs) averted. Compared to PCF alone, ACF for household contacts resulted in an ICER of $2155 per DALY averted. The addition of the Xpert MTB/RIF diagnostic test resulted in an ICER of $3275 per DALY averted within a PCF programme and $3399 per DALY averted when an ACF programme was included. Provider-initiated ACF of household contacts in an urban setting of Lima, Peru can be highly cost-effective, even including costs to seek out contacts and perform an Xpert/MTB RIF test. ACF including Xpert MTB/RIF was not cost-effective if TB cases detected had high rates of default from treatment or poor outcomes.
- 6 February 2017
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 145 (6) , 1107-1117
Cost-effectiveness of active case-finding of household contacts of pulmonary tuberculosis patients in a low HIV, tuberculosis-endemic urban area of Lima, Peru
SUMMARY We compared the cost-effectiveness (CE) of an active case-finding (ACF) programme for household contacts of tuberculosis (TB) cases enrolled in first-line treatment to routine passive case-finding (PCF) within an established national TB programme in Peru. Decision analysis was used to model detection of TB in household contacts through: (1) self-report of symptomatic cases for evaluation (PCF), (2) a provider-initiated ACF programme, (3) addition of an Xpert MTB/RIF diagnostic test for a single sputum sample from household contacts, and (4) all strategies combined. CE was calculated as the incremental cost-effectiveness ratio (ICER) in terms of US dollars per disability-adjusted life years (DALYs) averted. Compared to PCF alone, ACF for household contacts resulted in an ICER of $2155 per DALY averted. The addition of the Xpert MTB/RIF diagnostic test resulted in an ICER of $3275 per DALY averted within a PCF programme and $3399 per DALY averted when an ACF programme was included. Provider-initiated ACF of household contacts in an urban setting of Lima, Peru can be highly cost-effective, even including costs to seek out contacts and perform an Xpert/MTB RIF test. ACF including Xpert MTB/RIF was not cost-effective if TB cases detected had high rates of default from treatment or poor outcomes.
- Open Access
- 1 December 2016
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 54 (12) , 3028-3033
Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure
The Xpert MTB/RIF assay is both sensitive and specific as a diagnostic test. Xpert also reports quantitative output in cycle threshold ( C T ) values, which may provide a dynamic measure of sputum bacillary burden when used longitudinally. We evaluated the relationship between Xpert C T trajectory and drug exposure during tuberculosis (TB) treatment to assess the potential utility of Xpert C T for treatment monitoring. We obtained serial sputum samples from patients with smear-positive pulmonary TB who were consecutively enrolled at 10 international clinical trial sites participating in study 29X, a CDC-sponsored Tuberculosis Trials Consortium study evaluating the tolerability, safety, and antimicrobial activity of rifapentine at daily doses of up to 20 mg/kg of body weight. Xpert was performed at weeks 0, 2, 4, 6, 8, and 12. Longitudinal C T data were modeled using a nonlinear mixed effects model in relation to rifapentine exposure (area under the concentration-time curve [AUC]). The rate of change of C T was higher in subjects receiving rifapentine than in subjects receiving standard-dose rifampin. Moreover, rifapentine exposure, but not assigned dose, was significantly associated with rate of change in C T ( P = 0.02). The estimated increase in C T slope for every additional 100 μg · h/ml of rifapentine drug exposure (as measured by AUC) was 0.11 C T /week (95% confidence interval [CI], 0.05 to 0.17). Increasing rifapentine exposure is associated with a higher rate of change of Xpert C T , indicating faster clearance of Mycobacterium tuberculosis DNA. These data suggest that the quantitative outputs of the Xpert MTB/RIF assay may be useful as a dynamic measure of TB treatment response.
- 1 December 2016
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 54 (12) , 3028-3033
Open AccessXpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure
The Xpert MTB/RIF assay is both sensitive and specific as a diagnostic test. Xpert also reports quantitative output in cycle threshold ( C T ) values, which may provide a dynamic measure of sputum bacillary burden when used longitudinally. We evaluated the relationship between Xpert C T trajectory and drug exposure during tuberculosis (TB) treatment to assess the potential utility of Xpert C T for treatment monitoring. We obtained serial sputum samples from patients with smear-positive pulmonary TB who were consecutively enrolled at 10 international clinical trial sites participating in study 29X, a CDC-sponsored Tuberculosis Trials Consortium study evaluating the tolerability, safety, and antimicrobial activity of rifapentine at daily doses of up to 20 mg/kg of body weight. Xpert was performed at weeks 0, 2, 4, 6, 8, and 12. Longitudinal C T data were modeled using a nonlinear mixed effects model in relation to rifapentine exposure (area under the concentration-time curve [AUC]). The rate of change of C T was higher in subjects receiving rifapentine than in subjects receiving standard-dose rifampin. Moreover, rifapentine exposure, but not assigned dose, was significantly associated with rate of change in C T ( P = 0.02). The estimated increase in C T slope for every additional 100 μg · h/ml of rifapentine drug exposure (as measured by AUC) was 0.11 C T /week (95% confidence interval [CI], 0.05 to 0.17). Increasing rifapentine exposure is associated with a higher rate of change of Xpert C T , indicating faster clearance of Mycobacterium tuberculosis DNA. These data suggest that the quantitative outputs of the Xpert MTB/RIF assay may be useful as a dynamic measure of TB treatment response.
- 1 August 2016
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 54 (8) , 1984-1991
Feasibility and Operational Performance of Tuberculosis Detection by Loop-Mediated Isothermal Amplification Platform in Decentralized Settings: Results from a Multicenter Study
Background: Currently available nucleic acid amplification platforms for tuberculosis (TB) detection are not designed to be simple nor inexpensive enough to implement in decentralized settings in countries with a high burden of disease. The loop-mediated isothermal amplification platform (LAMP) may change this.
- 1 August 2016
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 54 (8) , 1984-1991
Feasibility and Operational Performance of Tuberculosis Detection by Loop-Mediated Isothermal Amplification Platform in Decentralized Settings: Results from a Multicenter Study
Background: Currently available nucleic acid amplification platforms for tuberculosis (TB) detection are not designed to be simple nor inexpensive enough to implement in decentralized settings in countries with a high burden of disease. The loop-mediated isothermal amplification platform (LAMP) may change this.
- 1 May 2016
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 20 (5) , 605-610
Manual MGIT™ system for the detection of Mycobacterium tuberculosis: insights from a high TB burden setting
OBJECTIVE: To evaluate the diagnostic performance of manual MGIT™ (MMGIT) compared to the gold standard, Löwenstein-Jensen (LJ), in the diagnosis of pulmonary tuberculosis (TB) in a high-burden setting.METHODS: Individuals with suspected TB enrolled in parallel diagnostic trials during 2007–2011 were included. Two samples were obtained from each patient and inoculated into MMGIT and LJ medium. Diagnostic tests were performed, and the incremental yield of a second test and time to detection (TTD) were calculated. Analyses were performed per patient and per sample. Gold standard was based on LJ culture.RESULTS: In the per patient and per sample analysis, we evaluated 1436 patients and 4142 samples. The sensitivity and specificity for smear and MMGIT per sample were respectively 89.9%/92.2% and 97.1%/98.9%. Contamination was observed in 1.4% of samples on MMGIT. The mean TTD (days) was 11.8 for MMGIT and 22.9 for LJ. The sensitivity and specificity for smear and MMGIT per patient were respectively 89.9% and 92.2% and 97.1% and 98.3%. A second MMGIT culture had an incremental yield of 1.6%.CONCLUSIONS: MMGIT has high sensitivity and specificity, regardless of smear result, with a 50% reduction in TTD compared to LJ. These features make MMGIT an acceptable TB diagnostic method for use in resource-limited settings.
- 1 May 2016
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 20 (5) , 605-610
Manual MGIT™ system for the detection of Mycobacterium tuberculosis: insights from a high TB burden setting
OBJECTIVE: To evaluate the diagnostic performance of manual MGIT™ (MMGIT) compared to the gold standard, Löwenstein-Jensen (LJ), in the diagnosis of pulmonary tuberculosis (TB) in a high-burden setting.METHODS: Individuals with suspected TB enrolled in parallel diagnostic trials during 2007–2011 were included. Two samples were obtained from each patient and inoculated into MMGIT and LJ medium. Diagnostic tests were performed, and the incremental yield of a second test and time to detection (TTD) were calculated. Analyses were performed per patient and per sample. Gold standard was based on LJ culture.RESULTS: In the per patient and per sample analysis, we evaluated 1436 patients and 4142 samples. The sensitivity and specificity for smear and MMGIT per sample were respectively 89.9%/92.2% and 97.1%/98.9%. Contamination was observed in 1.4% of samples on MMGIT. The mean TTD (days) was 11.8 for MMGIT and 22.9 for LJ. The sensitivity and specificity for smear and MMGIT per patient were respectively 89.9% and 92.2% and 97.1% and 98.3%. A second MMGIT culture had an incremental yield of 1.6%.CONCLUSIONS: MMGIT has high sensitivity and specificity, regardless of smear result, with a 50% reduction in TTD compared to LJ. These features make MMGIT an acceptable TB diagnostic method for use in resource-limited settings.
- Open Access
- 26 June 2015
- Published by Springer Nature in BMC Public Health
- Vol. 15 (1) , 1-11
Implementation of a stepped-wedge cluster randomized design in routine public health practice: design and application for a tuberculosis (TB) household contact study in a high burden area of Lima, Peru
We designed a pragmatic stepped-wedge cluster randomized controlled trial in order to evaluate provider-initiated evaluation of household contacts (HCs) of smear positive tuberculosis (TB) cases within a routine TB program in Lima, Peru. National TB program (NTP) officers of San Juan de Lurigancho District (Lima, Peru) and university-based researchers jointly designed a pragmatic stepped-wedge cluster randomized trial design in order to evaluate a planned active case finding (ACF) program for all HCs of smear-positive TB cases in 34 district healthcare centres. Randomization of time to intervention initiation was stratified by health centre TB case rate. The ACF intervention included provider-initiated home visits of all new sputum smear positive TB patients in order to evaluate household contacts for active TB. Active TB was diagnosed using symptom screening, sputum screening, chest x-ray and clinical evaluation. Once initiated, ACF was provided by NTP staff and integrated into the routine DOTS TB program activities. This study protocol describes the pragmatic stepped-wedge cluster randomized trial of active household contact evaluations within an NTP. The stepped-wedge design met overlapping needs of local TB programmers and researchers to adequately evaluate the large-scale roll out of a new control program in a TB endemic setting. Multiple planning meetings were required to develop the necessary networks and in order to understand the operations, needs and goals of the NTP staff and researchers collaborating on this project. The advantages and challenges of using this study design in practice and within existing routine TB programs in a middle-income country context are discussed. ClinicalTrials.gov NCT02174380. Registered 24 Jun 2014
- 26 June 2015
- Published by Springer Nature in BMC Public Health
- Vol. 15 (1) , 1-11
Open AccessImplementation of a stepped-wedge cluster randomized design in routine public health practice: design and application for a tuberculosis (TB) household contact study in a high burden area of Lima, Peru
We designed a pragmatic stepped-wedge cluster randomized controlled trial in order to evaluate provider-initiated evaluation of household contacts (HCs) of smear positive tuberculosis (TB) cases within a routine TB program in Lima, Peru. National TB program (NTP) officers of San Juan de Lurigancho District (Lima, Peru) and university-based researchers jointly designed a pragmatic stepped-wedge cluster randomized trial design in order to evaluate a planned active case finding (ACF) program for all HCs of smear-positive TB cases in 34 district healthcare centres. Randomization of time to intervention initiation was stratified by health centre TB case rate. The ACF intervention included provider-initiated home visits of all new sputum smear positive TB patients in order to evaluate household contacts for active TB. Active TB was diagnosed using symptom screening, sputum screening, chest x-ray and clinical evaluation. Once initiated, ACF was provided by NTP staff and integrated into the routine DOTS TB program activities. This study protocol describes the pragmatic stepped-wedge cluster randomized trial of active household contact evaluations within an NTP. The stepped-wedge design met overlapping needs of local TB programmers and researchers to adequately evaluate the large-scale roll out of a new control program in a TB endemic setting. Multiple planning meetings were required to develop the necessary networks and in order to understand the operations, needs and goals of the NTP staff and researchers collaborating on this project. The advantages and challenges of using this study design in practice and within existing routine TB programs in a middle-income country context are discussed. ClinicalTrials.gov NCT02174380. Registered 24 Jun 2014